Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism

Figures & data

Figure 1 Applanating surface of the centrally concave and circumferentially convex (CATS) prism.

Table 1 Table of Unique Patient and Eye Demographics in Test and Control Arms

Indiv. Measurements	Total	Latanoprost 0.005%	Timolol 0.5%
Unique eyes	36 pts./72 eyes	36 eyes from 18 pts.	36 eyes from 18 pts.
Male,Female	8,28	3,15	5,13
Age ±S.D.	61±14	60±15	63±15
Initial CCT (µm) ±S.D.	540±34	540±36	541±33
Initial CH (mmHg) ±S.D.	9.7±1.3	9.6±1.5	9.8±0.95
Initial GAT IOP (mmHg) ±S.D.	20.7±7.0	20.6±7.9	20.8±6.2
% by GAT/CATS initially below 21mmHg	61.1/38.9	63.9/33.3	58.3/44.0

Table 2 Timolol and Latanoprost Cohort Mean IOP Measurements and Standard Deviation at Treatment Examination Times

	Pre-Treatment	1 Month	3 Months	6 Months
Latanoprost cohort
Mean GAT	20.64	16.93	16.93	17.27
S.D.	2.57	1.12	1.13	1.31
Mean CATS	22.56	17.17	17.32	17.68
S.D.	2.65	1.21	1.09	1.32
CATS-GAT Paired Difference	2.02	0.23	0.39	0.41
S.D.	2.30	1.41	1.14	1.85
Timolol cohort
Mean GAT	20.83	16.27	18.04	18.95
S.D.	2.03	1.37	1.64	1.90
Mean CATS	22.03	17.42	18.38	19.59
S.D.	2.11	1.27	1.49	1.69
CATS-GAT Paired Difference	1.91	1.07	0.34	0.5
S.D.	2.02	1.77	1.54	1.5

Figure 2 Timolol and latanoprost cohort IOP measurements at treatment times.

Table 3 CATS and GAT IOP Reduction in Latanoprost 0.005% Test and Timolol 0.5% Control Arms at 6 Months

Prism	Latanoprost 0.005% mmHg	Timolol 0.5% mmHg	Difference (Lat-Tim) mmHg (p=homoscadastic)
CATS mmHg ± S.D.	6.5±5.9	2.8 ±6.7	3.7 (p=0.008)
GAT mmHg ± S.D.	4.6 ±5.2	3.3 ± 6.7	1.5 (p=0.08)
IOP drop (Pre-6 mos.) mmHg (p=paired)	1.9 (p=0.01)	−0.5 (p=0.23)

Figure 3 Non-response rates less than 20% reduction from baseline IOP in CATS and GAT measured IOP reduction using topical latanoprost 0.005% or alternatively timolol 0.5%.